A picture of service-bed compartment of the gamma spectrometry vehicle used in the experiment. by Antanas Bukartas (10023785)

Fig 2 - by Megan Armstrong (1782073)

CONSORT diagram for prospective survey recruitment. by Megan Armstrong (1782073)

Patient characteristics by medical conditions pre-and post-prescription law. by Megan Armstrong (1782073)

Opioid medication use and patient satisfaction after hospital discharge. by Megan Armstrong (1782073)

Number of days and MMEs/kg prescribed at discharge by days to law change. by Megan Armstrong (1782073)

High glucose induces a mild decrease in KIF5B but does not affect the overall content and distribution of tau, KIF1A and dynein in hippocampal cultures. by Filipa I. Baptista (145150)

Infection with <i>Shigella flexneri</i> M90T<i>ΔaroA</i> results in a decrease in TAMs number. by Katharina Galmbacher (252251)

Conditional ablation of <i>Ybx1</i> leads to a reduction in cortical progenitor cell pool and a decrease in cortical thickness. by Jian Zhang (1682)

Expanding Three-Coordinate Gold(I) Anticancer Agent Chemical Space by Charles E. Greif (21728091)

“…We report the synthesis and characterization of 14 complexes of the type (Au(R)[N̂N])⁺, where R = tunable biaryldialkyl phosphine ligands and [N̂N] = bidentate phenanthroline derivatives as anticancer agents. …”

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

ST2-104 decreases the Aβ_25-35-mediated increase in intracellular Ca²⁺. by Yingshi Ji (9013004)

Stress strain curves (from a1 to f1), stress—AE count plots (from a2 to f2) and stress—cumulative AE count plots (from a3 to f3) for the sample temperatures of 20°C, 50°C, 100°C, 1... by Nazlı Tunar Özcan (14833635)

Anthelmintics Derived from the Kinase Inhibitor SGI-1776 for the Treatment of Gastrointestinal Worm Infections by Mostafa A. Elfawal (22430138)

“…The unexpected SAR of compound <b>15</b> can be explained by computational modeling. We demonstrate the efficacy of optimized compound <b>50</b> as a new oral anthelmintic, which demonstrated better gut restriction properties and significantly reduced the fecundity of T. muris whipworm adults in infected mice. …”

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”

A decreased yield of RNP1, RNP2 and RNP5 formation in the presence of protein aGAR1 is counteracted by RNA-S by Bruno Charpentier (9519)

Whole sample storing experiment: Mean FECs of day 0, day 1 and day 2 for hookworm, <i>A</i>. <i>lumbricoides</i> and <i>T</i>. <i>trichiura</i>. by Felix Bosch (10024550)